Hemispherx Biopharma (HEB) Reports Q1 Loss of $0.02/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Hemispherx Biopharma Announces Financial Results for the Three Months Ended March 31, 2015
May 13, 2015 8:30 AM EDTPHILADELPHIA, May 13, 2015 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE MKT: HEB) announced its financial results for the three months ended March 31, 2015. The net loss (including non-cash effects) was approximately $3,445,000 or $(0.02) per share as compared to a net loss of $3,836,000 or ($0.02) per share for the same three month period in 2014. Cash, cash equivalents and marketable securities were approximately $17,005,000 at March 31, 2015 as compared to $16,108,000 as of December 31, 2014.
Our European subsidiary, Hemispherx Biopharma Europe N.V./S.A., received formal notification from the European Commission [EU/3/15/1480-EMA/OD/310/14] approving its Orphan Medicinal Product Application for Ampligen®, an... More
